Literature DB >> 17320010

Chest pain in emergency department patients: if the pain is relieved by nitroglycerin, is it more likely to be cardiac chest pain?

Robert Steele1, Timothy McNaughton, Melissa McConahy, John Lam.   

Abstract

INTRODUCTION: It is often believed that chest pain relieved by nitroglycerin is indicative of coronary artery disease origin.
OBJECTIVE: To determine if relief of chest pain with nitroglycerin can be used as a diagnostic test to help differentiate cardiac chest pain and non-cardiac chest pain.
DESIGN: Prospective observational cohort study with a 4-week follow-up of patients enrolled.
SETTING: Academic tertiary care hospital, with 60,000 visits/year. INCLUSION CRITERIA: Adult patients presenting to the emergency department with active chest pain who received nitroglycerin and were admitted for chest pain. EXCLUSION CRITERIA: Patients with acute myocardial infarction diagnosed after obtaining an ECG, patients whose chest pain could not be quantified, those for whom no cardiac work-up was done, or those who received emergent cardiac catheterization.
RESULTS: 270 patients were enrolled. Nitroglycerin relieved chest pain in 66% of the subjects. The diagnostic sensitivity of nitroglycerin to determine cardiac chest pain was 72% (64%-80%), and the specificity was 37% (34%-41%). The positive likelihood ratio for having coronary artery disease if nitroglycerin relieved chest pain was 1.1 (0.96-1.34). Telephone follow-up at 4 weeks was performed, with a 95% follow-up rate.
CONCLUSIONS: Relief of chest pain with nitroglycerin is not a reliable diagnostic test and does not distinguish between cardiac and non-cardiac chest pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17320010     DOI: 10.1017/s1481803500013671

Source DB:  PubMed          Journal:  CJEM        ISSN: 1481-8035            Impact factor:   2.410


  1 in total

1.  Is every chest pain a cardiac event? : an audit of patients with chest pain presenting to emergency services in India.

Authors:  Sahoo Saddichha; Mukul Kumar Saxena
Journal:  Intern Emerg Med       Date:  2009-04-15       Impact factor: 3.397

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.